Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.84 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.84 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.84 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.84 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.84 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.84 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.84 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.84 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.84 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.84 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.84 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.84 |
| ▸ | GAK | O14976 | 3/20 | 0.84 |
| ▸ | KDR | P35968 | 3/20 | 0.84 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.84 |
| ▸ | BUB1 | O43683 | 2/20 | 0.84 |
| ▸ | STK10 | O94804 | 2/20 | 0.84 |
| ▸ | ABL1 | P00519 | 2/20 | 0.84 |
| ▸ | LCK | P06239 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12426799 | 0.99 | EGFR (0.84) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL13882737 | 0.93 | EGFR (0.84) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL641765 | 0.92 | EGFR (0.84) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| Erlotinib SCHEMBL27974794 | 0.92 | EGFR (0.82) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| Cudc-101 SCHEMBL29350202 | 0.92 | HDAC3 (1.00) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL641667 | 0.92 | HDAC3 (1.00) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL13882718 | 0.92 | HDAC3 (0.88) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL8212688 | 0.92 | HDAC3 (1.00) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| Cudc-101 SCHEMBL93769 | 0.92 | HDAC3 (1.00) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| Cudc-101 SCHEMBL29379912 | 0.92 | HDAC3 (1.00) | EGFRERBB2HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198669-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MUSCULAR DISORDERS AND DYSTROPHIES, STEROID SIDE EFFECTS, AND INFLAMMATION | CHILDREN'S NATIONAL MEDICAL CENTER (US) | 2021-07-01 | — | — | US | disclosed |
| US-9108929-B2 | Quinazoline based EGFR inhibitors | CURIS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108929-B2 | Quinazoline based EGFR inhibitors | CURIS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-8349856-B2 | Quinazoline based EGFR inhibitors | CURIS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349856-B2 | Quinazoline based EGFR inhibitors | CURIS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-7977347-B2 | inhibitors of epidermal growth factor receptor tyrosine kinase; anticancer; 6-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)hexanoic acid | CURIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977347-B2 | inhibitors of epidermal growth factor receptor tyrosine kinase; anticancer; 6-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)hexanoic acid | CURIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198669-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MUSCULAR DISORDERS AND DYSTROPHIES, STEROID SIDE EFFECTS, AND INFLAMMATION | TNNC1, MYOF, MBNL1 | EGFR 4804/4885ERBB2 4225/4885HDAC3 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.